SGLT2 inhibitors may protect endothelial cells from increased glucose uptake and ROS production, inhibit EGFR kinase activity and thus prevent high glucose‐induced endothelial dysfunction and diabetic cardiovascular complications.28, 29. Here, SLC5A2 is linked to endothelial dysfunction.